Pharmaero ApS is a 50:50 joint venture between Scandinavian Health Ltd. (SHL Group), a significant player in the injectable device space, and Xellia Pharmaceuticals a prominent Active Pharmaceutical Ingredients and Finish Dosage Form supplier. Pharmaero develop products based on the novel Aqueous Droplet Inhaler; the ADI. The two first products provides anti-infective treatments localized to the lung and respiratory tract for out-patients. Other areas are currently being investigated together with several undisclosed parties.
Pharmaero was founded in 2009. The Company has already developed 2 anti-infective products based on the ADI platform. Both products have been divested to Xellia. Pharmaero maintains its focus on development of products for pulmonary infections but could work with all therapeutic areas.